Sex: M
Vaccine: TYP
Symptoms: Inappropriate schedule of product administration, No adverse event
Clinical narrative: The patient took the third dose of Vivotif one day earlier and the fourth dose took five days after first dose; Case reference number US-BN-2024-002572 is a spontaneous case initially received from a nurse via Med Communications (reference number: USBAV24-2554) on 30-Sep-2024 and concerns a 32-year-old male patient.   The patient's medical history and concomitant medication details were not provided.  On 26-Sep-2024, the patient took the first dose of Vivotif (batch number: *3004045, expiration date: 30-Oct-2024) one capsule*, orally, for typhoid immunization due to international travel.  On 28-Sep-2024, two days after the first dose of Vivotif, the patient took the second dose of Vivotif (batch number: *3004045, expiration date: 30-Oct-2024) one capsule*, orally.  On 29-Sep-2024, as reported one day earlier, three days after first dose of Vivotif, the patient took the third dose of Vivotif (batch number: *3004045, expiration date: 30-Oct-2024), one capsule*, orally (explicitly coded as 'inappropriate schedule of vaccine administered'). As reported, the patient took capsules correctly one hour before food, in the morning.  *On 01-Oct-2024, five days after the first dose of Vivotif, the patient took the fourth dose of Vivotif (batch number: 3004045, expiration date: 30-Oct-2024) one capsule, orally. (explicitly coded as 'inappropriate schedule of vaccine administered'). *  At the time of the *follow-up* report, it was *reported that the patient did not experience* any adverse event due to the Vivotif vaccination.  All follow-up information is blended into the case narrative above, with the latest information presented between asterisks (*).  Follow-up information received from the nurse on 09-Oct-2024: New information included patient initials, dosing information for Vivotif and confirmation that the patient did not experience any adverse event due to the Vivotif vaccination.; Reporter's Comments: A 32-year-old male patient took the third dose of Vivotif for typhoid immunization due to international travel, three days after the first dose was administered, which is considered as inappropriate schedule of vaccine administered. Five days after the first dose of Vivotif, the patient took the fourth dose of Vivotif, one capsule, orally which is also considered as inappropriate schedule of vaccine administered. The patient did not experience any adverse event due to the Vivotif vaccination. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A 32-year-old male patient took the third dose of Vivotif for typhoid immunization due to international travel, three days after the first dose was administered, which is considered as inappropriate schedule of vaccine administered. Five days after the first dose of Vivotif, the patient took the fourth dose of Vivotif, one capsule, orally which is also considered as inappropriate schedule of vaccine administered. The patient did not experience any adverse event due to the Vivotif vaccination. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.